Short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma

Table 4 Comparison of computed tomography perfusion parameters of the lesions in the two groups of patients

Perfusion parameters	Study group, n = 49	Control group, n = 49	Z value	P value
BV, mL/(100 g/min)
Before treatment	23.16 ± 3.29	22.57 ± 4.02	0.795	0.429
After 3 mo of treatment	8.40 ± 2.20	10.01 ± 2.54	-3.354	0.001
PS, mL/(100 g/min)
Before treatment	27.17 ± 5.48	26.20 ± 5.81	0.850	0.397
After 3 mo of treatment	12.64 ± 2.60	14.20 ± 3.13	-2.684	0.009
BF, mL/(100 g/min)
Before treatment	254.8 ± 58.1	247.6 ± 63.4	0.586	0.559
After 3 mo of treatment	83.0 ± 24.7	100.2 ± 32.5	-2.949	0.004
HAF, %
Before treatment	0.67 ± 0.17	0.64 ± 0.17	0.873	0.385
After 3 mo of treatment	0.24 ± 0.08	0.31 ± 0.10	-3.826	0.000
MTT, s
Before treatment	7.60 ± 1.63	7.80 ± 1.55	-0.622	0.535
After 3 mo of treatment	5.20 ± 0.81	5.83 ± 0.96	-3.511	0.001

Data are presented as mean ± SD. Control group: Treated with transarterial chemoembolization (TACE); Study group: Treated with TACE and radioactive iodine implantation. BF: Blood flow; BV: Blood volume; HAF: Hepatic artery flow; MTT: Mean transit time; PS: Permeability surface.